LÃ¦rke Smidt Gasbjerg

List of Publications by Year
in descending order

#	Article	IF	Citations
1	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes, 2019, 68, 906-917.	0.3	118
2	The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. Diabetes, 2017, 66, 2363-2371.	0.3	88
3	Speciesâ€specific action of (Pro3)GIP â€" a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. British Journal of Pharmacology, 2016, 173, 27-38.	2.7	86
4	Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regulatory Peptides, 2012, 179, 91-100.	1.9	81
5	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia, 2019, 62, 665-675.	2.9	81
6	Nâ€terminally and Câ€terminally truncated forms of glucoseâ€dependent insulinotropic polypeptide are highâ€affinity competitive antagonists of the human GIP receptor. British Journal of Pharmacology, 2016, 173, 826-838.	2.7	72
7	GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia, 2018, 61, 413-423.	2.9	66
8	Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors. Biochemical Pharmacology, 2018, 150, 97-107.	2.0	65
9	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides, 2020, 125, 170183.	1.2	61
10	Biased and Constitutive Signaling in the CC-chemokine Receptor CCR5 by Manipulating the Interface between Transmembrane Helices 6 and 7. Journal of Biological Chemistry, 2013, 288, 12511-12521.	1.6	59
11	Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides, 2018, 100, 173-181.	1.2	56
12	GIP(3â€"30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release. Biochemical Pharmacology, 2017, 131, 78-88.	2.0	55
13	GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men. Bone, 2019, 125, 178-185.	1.4	45
14	The Role of Incretins on Insulin Function and Glucose Homeostasis. Endocrinology, 2021, 162, .	1.4	43
15	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2953-2960.	1.8	41
16	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. Diabetes Care, 2020, 43, 588-596.	4.3	38
17	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e725-e738.	1.8	37
18	The bile acidâ€sequestering resin sevelamer eliminates the acute <scp>GLP</scp>â€1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 362-369.	2.2	33

#	Article	IF	Citations
19	Effect of Intracoronary and Intravenous Melatonin on Myocardial Salvage Index in Patients with ST-Elevation Myocardial Infarction: a Randomized Placebo Controlled Trial. Journal of Cardiovascular Translational Research, 2017, 10, 470-479.	1.1	32
20	GLP-1 and GIP receptor signaling in beta cells â€“ A review of receptor interactions and co-stimulation. Peptides, 2022, 151, 170749.	1.2	29
21	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. Cell Reports, 2017, 21, 1452-1460.	2.9	28
22	Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. Peptides, 2020, 125, 170174.	1.2	27
23	Molecular interactions of full-length and truncated GIP peptides with the GIP receptor â€“ A comprehensive review. Peptides, 2020, 125, 170224.	1.2	27
24	GIP and the gut-bone axis â€“ Physiological, pathophysiological and potential therapeutic implications. Peptides, 2020, 125, 170197.	1.2	25
25	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Bone, 2020, 140, 115553.	1.4	25
26	Signaling via G proteins mediates tumorigenic effects of GPR87. Cellular Signalling, 2017, 30, 9-18.	1.7	21
27	Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats. Frontiers in Endocrinology, 2019, 10, 492.	1.5	21
28	Effects of endogenous GIP in patients with type 2 diabetes. European Journal of Endocrinology, 2021, 185, 33-45.	1.9	21
29	LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. Cell Reports Medicine, 2022, 3, 100582.	3.3	21
30	GIPâ€™s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3â€“30)NH2. Bone, 2020, 130, 115079.	1.4	20
31	Extracellular Disulfide Bridges Serve Different Purposes in Two Homologous Chemokine Receptors, CCR1 and CCR5. Molecular Pharmacology, 2013, 84, 335-345.	1.0	18
32	GIPâ€™s involvement in the pathophysiology of type 2 diabetes. Peptides, 2020, 125, 170178.	1.2	18
33	The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. European Journal of Endocrinology, 2021, 184, 383-394.	1.9	15
34	Exendin(9â€39)<scp>NH₂</scp>: Recommendations for clinical use based on a systematic literature review. Diabetes, Obesity and Metabolism, 2021, 23, 2419-2436.	2.2	15
35	Doseâ€dependent efficacy of the glucoseâ€dependent insulinotropic polypeptide (<scp>GIP)</scp> receptor antagonist <scp>GIP</scp>(3â€30)<scp>NH₂</scp> on <scp>GIP</scp> actions in humans. Diabetes, Obesity and Metabolism, 2021, 23, 68-74.	2.2	14
36	GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. Pharmacological Research, 2022, 176, 106058.	3.1	13

#	Article	IF	Citations
37	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. Diabetes, 2019, 68, .	0.3	10
38	GIP(3-30)NH2 â€“ a tool for the study of GIP physiology. Current Opinion in Pharmacology, 2020, 55, 31-40.	1.7	8
39	Gluco-metabolic effects of oral and intravenous alcohol administration in men. Endocrine Connections, 2019, 8, 1372-1382.	0.8	7
40	Acute concomitant glucoseâ€dependent insulinotropic polypeptide receptor antagonism during glucagonâ€like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. Diabetes, Obesity and Metabolism, 2022, 24, 1882-1887.	2.2	5
41	Nâ€terminal alterations turn the gut hormone GLPâ€2 into an antagonist with gradual loss of GLPâ€2 receptor selectivity towards more GLPâ€1 receptor interaction. British Journal of Pharmacology, 2022, 179, 4473-4485.	2.7	5
42	The Combination of Fosfomycin, Metronidazole, and Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor is Stable in vitro and Has Maintained Antibacterial Activity. Drug Research, 2018, 68, 349-354.	0.7	4
43	The effect of acute intragastric vs. intravenous alcohol administration on inflammation markers, blood lipids and gallbladder motility in healthy men. Alcohol, 2020, 87, 29-37.	0.8	4
44	Worsening Postural Tachycardia Syndrome Is Associated With Increased Glucose-Dependent Insulinotropic Polypeptide Secretion. Hypertension, 2022, 79, HYPERTENSIONAHA12117852.	1.3	4
45	Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects. Diabetes, 2018, 67, 145-OR.	0.3	3
46	89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes. Diabetes, 2020, 69, .	0.3	3
47	Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults. European Journal of Endocrinology, 2021, 185, 23-32.	1.9	2
48	1976-P: Physiological Effects of GIP(1-30)NH2 in Healthy Subjects. Diabetes, 2019, 68, 1976-P.	0.3	1
49	The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection. Frontiers in Endocrinology, 0, 13, .	1.5	1
50	Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes. Diabetes, 0, , .	0.3	1
51	The Effect of Ethanol on Inflammation Markers and FGF-21 in Healthy Individuals. Diabetes, 2018, 67, .	0.3	0
52	Gastric Aspiration Improves Postprandial Glucose Tolerance Without Causing a Compensatory Increase in Appetite and Food Intake. Obesity Surgery, 2022, 32, 1385-1390.	1.1	0